iCarbonX Overview
Pro stress-test →iCarbonX combines genomics with other health factors such as metabolites, bacteria and lifestyle choices to create a digitalized form of life. The company's core business involves creating a health-focused bioinformatics platform that analyzes multi-omics data—including genomics, metabolomics, and proteomics—alongside phenotypic and behavioral information. The analysis is used by individuals for health management and by pharma companies for drug development.
Strategic Profile
Pro stress-test →Founded in October 2015 by Chinese genomicist Jun Wang, former CEO of Beijing Genomic Institute (BGI), iCarbonX was touted as the "next Google in biotech". The company has raised $366M in funding over 5 rounds and is valued at $1B, positioning itself as a data aggregator leveraging BGI's world-class genomics heritage to build an ecosystem combining AI, multi-omics analysis, and personalized health solutions for global markets.
Competitive Landscape
Pro stress-test →iCarbonX faces competition from personalized medicine companies like Wuxi NextCODE and Human Longevity, as well as from startups attacking different aspects of the genomics spectrum. Top competitors include Lifebit, Cellworks, and Immuneering Corporation. The company's ecosystem approach differentiates it, but precision medicine data interpretation challenges remain a structural headwind across the sector.
Industry Context
iCarbonX operates in Precision medicine and genomic bioinformatics platforms.
Key facts
Founded: 2015 · Headquarters: Shenzhen, China · Employees: 60-128 · Revenue: N/A · Market cap: N/A